Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Synt:em licenses Pep:trans technology to Corixa for vaccine development

March 13, 2002

AtheroGenics begins phase I trial of transplant rejection drug AGI-1096

March 8, 2002

B7 protein PD-L2 described in patent

March 6, 2002

OrBec receives orphan drug status in Europe for intestinal graft-vs.-host disease

March 4, 2002

Effects on dendritic cell function of the immunomodulator R-848

March 4, 2002

Avant signs research agreement with International Vaccine Institute for cholera vaccine

Feb. 25, 2002

Nongenotoxic porphyrin derivatives from Eukarion effective as ROS catalytic scavengers

Feb. 22, 2002

Cholera vaccines offered for licensing by NIH

Feb. 20, 2002

Mutant heat-labile enterotoxin as a potent adjuvant for oral influenza vaccination

Feb. 18, 2002

Pfizer synthesizes JAK3 inhibitors potentially useful as immunosuppressants

Feb. 15, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....